Literature DB >> 11879588

Cholangiocarcinoma of the Hepatic Hilum (Klatskin Tumor).

Valerie Byrnes1, Nezam Afdhal.   

Abstract

Since the description by Klatskin in 1965, the management of patients with adenocarcinoma of the hepatic bile duct bifurcation is viewed as a challenging clinical problem with a relatively poor prognosis. Surgery continues to be the mainstay of therapy. Complete resection of the tumor with negative histologic margins offers the best possibility of long-term survival, and hepatic resection is a critical component of the operative approach. Adjuvant chemoradiotherapy has failed to provide a significant survival benefit. Orthotopic liver transplantation for otherwise unresectable lesions remains controversial, as tumor recurrence has been reported in more than 90% of patients. With the shortage of organs, such patients to be selected carefully for transplanation. For patients who present with widespread disease and those with high operative risks, advances in interventional radiology and endoscopy have facilitated nonsurgical management options. Biliary decompression using expandable metallic stents provides superior patency and decreased frequency of hospitalization when compared with plastic stents. Moreover, patients treated with expandable metal stents have survival rates comparable with those who undergo surgical decompression, with fewer early complications. The benefit of external beam radiotherapy for palliation of proximal cholangiocarcinoma is uncertain. Radiotherapy in conjunction with biliary stenting has a survival benefit over stenting alone, but is not without potential toxicity. It should be considered as an adjunct to biliary decompression in all patients with good performance status, because modern conformal CT-based dosimetry can minimize toxicity to normal adjacent tissue. Photodynamic therapy is emerging as a new palliative treatment modality for patients with unresectable tumors in whom stenting has failed. It offers the advantage of an endoscopic delivery system, and unlike radiotherapy, photodynamic therapy may be delivered repeatedly.

Entities:  

Year:  2002        PMID: 11879588     DOI: 10.1007/s11938-002-0055-5

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  37 in total

1.  Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma--a single center experience.

Authors:  M F Gerhards; T M van Gulik; L T de Wit; H Obertop; D J Gouma
Journal:  Surgery       Date:  2000-04       Impact factor: 3.982

2.  Palliative treatment in patients with unresectable hilar cholangiocarcinoma: results of endoscopic drainage in patients with type III and IV hilar cholangiocarcinoma.

Authors:  M F Gerhards; D den Hartog; E A Rauws; T M van Gulik; D González González; J S Lameris; L T de Wit; D J Gouma
Journal:  Eur J Surg       Date:  2001-04

3.  Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.

Authors:  M Raderer; M H Hejna; J B Valencak; G V Kornek; G S Weinländer; E Bareck; J Lenauer; T Brodowicz; F Lang; W Scheithauer
Journal:  Oncology       Date:  1999-04       Impact factor: 2.935

Review 4.  Cholangiocarcinoma.

Authors:  C J Yeo; H A Pitt; J L Cameron
Journal:  Surg Clin North Am       Date:  1990-12       Impact factor: 2.741

5.  Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.

Authors:  Y Z Patt; D V Jones; A Hoque; R Lozano; A Markowitz; I Raijman; P Lynch; C Charnsangavej
Journal:  J Clin Oncol       Date:  1996-08       Impact factor: 44.544

6.  Changing strategies in diagnosis and management of hilar cholangiocarcinoma.

Authors:  J Figueras; L Llado; C Valls; T Serrano; E Ramos; J Fabregat; A Rafecas; J Torras; E Jaurrieta
Journal:  Liver Transpl       Date:  2000-11       Impact factor: 5.799

7.  p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis.

Authors:  P M Rizzi; S D Ryder; B Portmann; J K Ramage; N V Naoumov; R Williams
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

8.  Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology.

Authors:  K Ohashi; Y Nakajima; H Kanehiro; M Tsutsumi; J Taki; Y Aomatsu; A Yoshimura; S Ko; T Kin; K Yagura
Journal:  Gastroenterology       Date:  1995-11       Impact factor: 22.682

9.  Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction.

Authors:  A C Smith; J F Dowsett; R C Russell; A R Hatfield; P B Cotton
Journal:  Lancet       Date:  1994-12-17       Impact factor: 79.321

10.  Preliminary results of a new covered biliary metal stent for malignant biliary obstruction.

Authors:  C S Shim; Y H Lee; Y D Cho; H K Bong; J O Kim; J Y Cho; Y S Kim; J S Lee; M S Lee; S G Hwang; K M Shin
Journal:  Endoscopy       Date:  1998-05       Impact factor: 10.093

View more
  6 in total

1.  Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma.

Authors:  Kawin Leelawat; Siriluck Narong; Jerasak Wannaprasert; Thawee Ratanashu-ek
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

2.  Diagnosis, Staging, and Treatment of Cholangiocarcinoma.

Authors:  Jung-Hwan Yoon; Gregory J. Gores
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

3.  Optimal biliary drainage for inoperable Klatskin's tumor based on Bismuth type.

Authors:  Sang Hyub Lee; Joo Kyung Park; Won Jae Yoon; Jun Kyu Lee; Ji Kon Ryu; Yong Bum Yoon; Yong-Tae Kim
Journal:  World J Gastroenterol       Date:  2007-08-07       Impact factor: 5.742

4.  The tumor-selective viral protein apoptin effectively kills human biliary tract cancer cells.

Authors:  Alexandra M Pietersen; Saskia A Rutjes; Joost van Tongeren; Ronald Vogels; John G Wesseling; Mathieu H M Noteborn
Journal:  J Mol Med (Berl)       Date:  2003-11-28       Impact factor: 4.599

Review 5.  Effect of preoperative cholangitis on prognosis of patients with hilar cholangiocarcinoma: A systematic review and meta-analysis.

Authors:  Yudong Wang; Wenkang Fu; Zengwei Tang; Wenbo Meng; Wence Zhou; Xun Li
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

6.  Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma.

Authors:  Yongjiang Ba; Ping Yue; Joseph W Leung; Haiping Wang; Yanyan Lin; Bing Bai; Xiaoliang Zhu; Lei Zhang; Kexiang Zhu; Wenhui Wang; Wenbo Meng; Wence Zhou; Ying Liu; Xun Li
Journal:  Endosc Int Open       Date:  2020-01-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.